Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18603132 | 1.00 | CYP2D6 (0.55) | CYP2D6TSHR | |
| SCHEMBL19611532 | 0.85 | CYP2D6 (0.50) | CYP2D6 | |
| SCHEMBL19611531 | 0.85 | CYP2D6 (0.50) | CYP2D6 | |
| SCHEMBL20295208 | 0.73 | CYP2D6 (1.00) | CYP2D6TSHR | |
| SCHEMBL13732300 | 0.72 | — | — | |
| SCHEMBL13732301 | 0.72 | — | — | |
| SCHEMBL11232764 | 0.69 | — | — | |
| SCHEMBL1343565 | 0.69 | CYP2D6 (0.48) | CYP2D6 | |
| SCHEMBL1343560 | 0.69 | CYP2D6 (0.48) | CYP2D6 | |
| SCHEMBL23414729 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2020-05-07 | — | — | US | disclosed |
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2020-05-07 | — | — | US | disclosed |
| US-10562869-B2 | Oxadiazole compounds | REMYND NV (BE) | 2020-02-18 | — | — | US | disclosed |
| US-10562869-B2 | Oxadiazole compounds | REMYND NV (BE) | 2020-02-18 | — | — | US | disclosed |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | disclosed |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | disclosed |
| EP-2686312-B1 | N-CYCLOPROPYL-N-PIPERIDINYLBENZAMIDES AS GPR119 MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015140130-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2015-09-24 | — | — | WO | disclosed |
| US-8822471-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-8822471-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-20130065906-A1 | New compounds, pharmaceutical compositions and uses thereof | NEUROCRINE BIOSCIENCES, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065906-A1 | New compounds, pharmaceutical compositions and uses thereof | NEUROCRINE BIOSCIENCES, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| WO-2012123449-A1 | N- CYCLOPROPYL - N- PIPERIDINYLBENZAMIDES AS GPR119 MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065906-A1 | New compounds, pharmaceutical compositions and uses thereof | GPR119, GPR55, GPR65 | CYP2D6 664/4885TSHR 502/4885 |
| US-10562869-B2 | Oxadiazole compounds | OXA1L, PSEN1, MAPT | CYP2D6 739/4885TSHR 1833/4885 |
| US-20200140400-A1 | OXADIAZOLE COMPOUNDS | OXA1L, PSEN1, MAPT | CYP2D6 873/4885TSHR 1962/4885 |
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | OXA1L, PSEN1, MAPT | CYP2D6 739/4885TSHR 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.